2014 was a stellar year in biotech, for investors as well as patients.
Here’s to an even better 2015. Happy new year!
At PropThink, our goal has always been to provide actionable research on the healthcare and biotechnology sectors. This means making our research pertinent, and not just sending out commentary for the sake of commentary. One of our focuses for the new year is providing a more defined Call to Action in our Premium trade alerts, distilling the “action” in our research to a more digestible format for the average investor. We began this practice in mid-2014, partly in order to more precisely track performance, but we’re looking to simplify further.
Helping novice investors navigate the complicated and sometimes murky world of healthcare is one of our primary goals, which is why we’re working to make our research as approachable as possible. In our Premium Trade alerts you’ll find a summary of the trade, a well-defined entrance price, an additional hedging or options strategy, and a proposed timeline. Of course, our contributors are still providing the same great in-depth research, we’re just improving the format for investors who may not already have experience in the healthcare sector. Here’s how it looks:
Once a trade is “on” we’ll follow up with a Sell Alert or update when the trade has run its course, explaining appropriate exit prices or outlining any changes to the idea.
In conjunction with the new year, we’re offering our readers $200 off of an ANNUAL subscription to PropThink Premium. You’ll get all of our proprietary trades and research in 2015, a year that’s already shaping up to be tremendous as the biotechnology industry finally comes of age. With $200 off, that’s essentially FIVE months of PropThink Premium free (based on a typical $99/month subscription) in the new year.
Click here to take advantage of PropThink Premium at a $200 discount. Use coupon code RINGITIN2015 when checking out, valid through Monday night, January 5.
AND USE COUPON CODE:
RINGITIN2015
Best wishes in 2015!
The PropThink Editorial Team
